.webp)
In a move positioned as a cornerstone of its broader drug-pricing agenda, the administration of Donald Trump announced a new agreement Thursday with biotechnology firm Regeneron aimed at reducing the cost of prescription medications in the United States.
Under the terms of the deal, Regeneron will lower prices across all of its existing and future treatments within the Medicaid program. The agreement also includes a significant price reduction for its cholesterol drug Praluent, which will be offered at $225 through the administration’s discounted drug platform, TrumpRx.
The announcement arrives as economic pressures—from healthcare to everyday essentials—continue to weigh heavily on American households ahead of the November midterm elections. The administration has increasingly framed its pharmaceutical pricing strategy as a form of direct financial relief for consumers, while also pushing a “most-favored-nation” approach designed to align U.S. drug prices with those in other developed countries.
Regeneron’s agreement marks the final deal among 17 major pharmaceutical companies that were previously urged by the White House to adopt similar pricing concessions. Speaking from the White House, Trump underscored the significance of the discounts, suggesting they warranted national attention, while also acknowledging the unpredictability of electoral outcomes despite such policy moves.
The partnership also carries a historical dimension. During his first term in 2020, Trump received an experimental antibody treatment developed by Regeneron while hospitalized with COVID-19—an episode that led to public praise of the company following his recovery.
Beyond pricing adjustments, Regeneron has committed to investing $27 billion in U.S.-based research, development, and manufacturing. Such pledges have often been tied to broader policy incentives, including relief from trade-related pressures.
In a parallel development, the company confirmed that its gene therapy Otarmeni—targeting a rare congenital form of hearing loss—has received approval from the U.S. Food and Drug Administration and will be made available at no cost to eligible patients. The therapy was cleared under the agency’s Commissioner’s National Priority Voucher program, a mechanism that has drawn scrutiny from congressional Democrats, who have raised concerns about its use in connection with pricing negotiations.
While administration officials have characterized these drug-pricing agreements as transformative, key contractual details remain undisclosed. Responding to congressional inquiries, Robert F. Kennedy Jr. indicated that only non-proprietary elements of the agreements would be shared publicly. Both Trump and Kennedy have called on Congress to formalize the framework into law.
The broader initiative has not been without setbacks. Earlier this week, a central component involving weight-loss drug manufacturers faltered after Medicare delayed implementation of a coverage program for GLP-1 treatments.
Ultimately, drug pricing in the United States remains shaped by a complex mix of market competition, insurance coverage, and government policy. While programs like Medicaid and Medicare already limit out-of-pocket costs for many patients, lower baseline drug prices could ease the financial burden on state budgets that help sustain those systems.